Current status and future of cancer vaccines: A bibliographic study

Yu, Rui; Zhao, Fangmin; Xu, Zeting; Zhang, Gaochenxi; Du, Bingqing; Shu, Qijin

doi:10.1016/j.heliyon.2024.e24404

Cited by 5 publications

(1 citation statement)

References 80 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the private nature of neoantigens complicates the development of universal vaccines [51] . Furthermore, while it was previously believed that ovarian tumors lacked a sufficient mutation load for neoantigen-based therapy, a study revealed the presence of numerous neoantigens and specific T cells in OC patients [52] . Autologous vaccines might have a pivotal role in the advancement of cancer immunotherapy [53] .…”

Section: Vaccinesmentioning

confidence: 99%

Navigating immunotherapy for ovarian cancer: current landscape and future perspectives

Capuozzo,

Ferrara,

Cinque

et al. 2024

J Cancer Metastasis Treat

View full text Add to dashboard Cite

Ovarian cancer (OC) is the leading cause of death related to gynecologic malignancies, with recurrence occurring frequently despite significant advances in surgical interventions and chemotherapy. Therefore, novel therapies are necessary to improve the long-term prognosis of the disease. Immunotherapy holds promise in OC treatment by harnessing the potential of the immune system to combat neoplastic cells. The effectiveness of immunotherapy has been demonstrated in numerous cancers and subsequently integrated into clinical practice. However, despite initial preclinical findings suggesting an immunogenic microenvironment in OC, immune checkpoint inhibitors have not shown significant outcomes in clinical studies thus far. Further investigation is needed to fully understand the role of immunity in OC and to develop more effective therapeutic strategies, including combinatorial approaches and the identification of predictive biomarkers for more accurate patient selection for immunotherapy.

show abstract

Section: Vaccinesmentioning

confidence: 99%

Navigating immunotherapy for ovarian cancer: current landscape and future perspectives

Capuozzo,

Ferrara,

Cinque

et al. 2024

J Cancer Metastasis Treat

View full text Add to dashboard Cite

show abstract

Advances in Therapeutic Cancer Vaccines, Their Obstacles, and Prospects Toward Tumor Immunotherapy

Eskandari,

Leow,

Rahman

et al. 2024

Mol Biotechnol

View full text Add to dashboard Cite

Doxorubicin-induced Immunogenic Cell Death Impairs Tumor Progression and Distant Metastasis in a 4T1 Breast Cancer Tumor Model

Cardador,

de Castro,

de Castro

et al. 2024

CPD

View full text Add to dashboard Cite

Introduction: Cancer is an individual disease and its formation and development are specific to each host. Conventional treatments are ineffective in complex cases, such as metastasis, and have severe adverse side effects. New strategies are needed to address the problem, and the use of immunogenic cell death (ICD) as a trigger or booster of the immune system through the exposure of damage-associated molecular patterns, along with tumor antigens, by cancerous cells is presented as an immunization approach in this work. Methods: For this purpose, 4T1 cells were exposed to doxorubicin (DOX) for 24 hours and then, these cells undergoing ICD were subcutaneously administered to mice. The ICD induction by DOX on 4T1 was assessed by flow cytometry and image analysis. This immunization process was performed three times and after the last administration, the immunized mice were challenged with a subcutaneous xenograft of live cancer cells. Results: The results demonstrate that the mice immunized with cells undergoing ICD after exposure to DOX presented no primary tumor or indications of distant metastatic lesion development. Conclusion: In summary, our findings indicate that the immunization process utilizing ICD is indeed efficacious in managing this aggressive form of pre-clinical breast cancer.

show abstract

Current status and future of cancer vaccines: A bibliographic study

Cited by 5 publications

References 80 publications

Navigating immunotherapy for ovarian cancer: current landscape and future perspectives

Navigating immunotherapy for ovarian cancer: current landscape and future perspectives

Advances in Therapeutic Cancer Vaccines, Their Obstacles, and Prospects Toward Tumor Immunotherapy

Doxorubicin-induced Immunogenic Cell Death Impairs Tumor Progression and Distant Metastasis in a 4T1 Breast Cancer Tumor Model

Contact Info

Product

Resources

About